Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICER's Ambitious 2018 Review Agenda Takes On Groundbreaking Treatments

Executive Summary

Institute for Clinical and Economic Review plans to evaluate the cost effectiveness of gene therapy, CAR-T drugs and tissue-agnostic cancer drugs, among other treatments, in 2018.

Advertisement

Related Content

Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS
Policy Prescriptions: Kite's CAR-T; Price And Value Scrutiny; Biosimilars; Manufacturing Missteps
Momentum Builds For Tomorrow's More Convenient Hemophilia Drugs
Novartis' CAR-T Poised For The Market After Unanimous FDA Adcomm Review
ICER Eyes Gene Therapy: Category-wide Policy In Works As Spark Moves To Approval
Loxo Sees Larotrectinib As Model Form Of Oncology Drug Development
Teva Clinches Third Place In CGRP Race With A Phase III Migraine Win
Kite On Course For FDA Filing On Positive CAR-T Durability Data

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS121300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel